Lastly, despite the clinical efficacy and safety of TGF-β inhibitors in multiple clinical trials for solid tumors, they have not yet reached practical application due to the risk of unintentional tumor growth and inflammatory effects46. Here, TGFB1 is linked to neoplasm.